Trastuzumab rezetecan for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, trastuzumab rezetecan, for women with breast cancer that has come back or spread and cannot be removed by surgery. It's for those who haven't had chemotherapy for advanced disease but have tried hormone therapy and it stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75.
- Your breast cancer has returned or spread and cannot be removed by surgery.
- You have not had chemotherapy for advanced cancer, but you have tried at least one hormone therapy that no longer works.
- Your cancer has gotten worse on recent treatment, as shown by scans.
- You are able to take care of yourself (ECOG score 0 or 1).
- You agree to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (trastuzumab rezetecan and adebrelimab) against standard treatments for women with triple-negative breast cancer that wasn't completely removed by chemotherapy. The goal is to see if this combination works better at preventing the cancer from coming back.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
This trial tests a new targeted drug called trastuzumab rezetecan (T-DXh) for patients with HER2-positive breast cancer who didn't have a complete response to standard chemotherapy and targeted drugs. The goal is to see if this new drug can help shrink remaining cancer.
This study tests a new drug (trastuzumab rezetecan) for advanced solid tumors that have a protein called HER2 on their surface. The drug combines an antibody that targets HER2 with a chemotherapy component. It's designed for cancers that have grown despite prior treatment or have no good alternatives.
This trial tests two new antibody-based drugs (trastuzumab rezetecan and trastuzumab deruxtecan) designed to treat advanced breast cancer that has spread or cannot be removed with surgery. These drugs target HER2, a protein found on certain cancer cells, and may help patients whose cancer has progressed after previous treatment with trastuzumab and chemotherapy.
This trial tests a targeted therapy called trastuzumab deruxtecan for people with advanced breast cancer. It aims to see how well the treatment works and how safe it is.
Hear when a new Unresectable Locally Recurrent Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.